Login with your work email address to view charts. No credit card required.
| Art Unit: | 1632 — Chemistry: molecular biology and microbiology |
|---|---|
| Group: | 1630 — Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry |
| Classes: |
424 — Drug, bio-affecting and body treating compositions 435 — Chemistry: molecular biology and microbiology 800 — Multicellular living organisms and unmodified parts thereof and related processes 536 — Organic compounds -- part of the class 532-570 series 514 — Drug, bio-affecting and body treating compositions |
| Phone: | Available with subscription |
| Email: | Available with subscription |
| 3-Year Grant rate: | 0% over 49 cases |
|---|---|
| Difficulty: | Extremely Hard |
| Difficulty Percentile: | 100th
|
With Examiner Abeyratne-Perera, you have a 0% chance of getting an issued patent by 3 years after the first office action. Examiner Abeyratne-Perera is an extremely hard examiner and in the 100th percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Abeyratne-Perera, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Abeyratne-Perera's grant rate is lower than that of Art Unit 1632 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Abeyratne-Perera | 0.0 |
| Art Unit 1632 | 2.3 |
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.